New Cybersecurity Features Protect Facilities with Remote Operations

Article

Honeywell Forge Cybersecurity Suite’s improved industrial-grade remote access and added protection and risk monitoring aids remote operations.

A new version of Honeywell’s Forge Cybersecurity Suite includes several enhancements to help ensure business continuity in the face of mounting cyberthreats, uncertain global business conditions, and continued supply chain disruption associated with remote operations, the company announced in a June 25, 2020 press release. Features in the Honeywell Forge Cybersecurity Suite release (R200) include enhanced industrial-grade remote access, increased asset discovery capabilities with active and passive functionality, and improved cybersecurity risk monitoring.

“As more operators of critical infrastructure and facilities move to support remote work, they’re increasingly vulnerable to cybersecurity issues,” said Jeff Zindel, vice-president and general manager, Honeywell Connected Enterprise Cybersecurity, in the press release. “The Honeywell Forge Cybersecurity Suite helps customers increase productivity by providing the next level of protection required for more secure remote operations and better securing operational technology environments with asset discovery, inventory and continuous monitoring, as well as risk and compliance management.”

A single dashboard centralizes security operations and asset security management. It can help increase cyber-risk visibility while also decreasing cybersecurity management inefficiencies, at a single facility or across an enterprise. It addresses safely moving and using operations data, strengthening endpoint and network security, and improving cybersecurity compliance. Remote access can be provided to vendors and managed with greater security.

Three versions are available: Enterprise Core, Enterprise Premium, and Site. It can be deployed either as a subscription or through Honeywell Managed Security Services. 

Source: Honeywell 
 

Recent Videos
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
© 2024 MJH Life Sciences

All rights reserved.